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 Photorefractive keratectomy (PRK) is commonly used to 
correct refractive error of cornea. Postoperative therapy rou-
tinely consists of administration of steroid eye drops, because 
glucocorticoids (GCs) have a dehydrating effect in the corneal 
stroma. GCs help maintain refractive stability and inhibits 
stromal scarring, rethickening, and consequent regression of 
refraction [1-4] although their molecular mechanism is not 
clearly known [5]. Topical or systemic administration of GCs 
may produce a rise in intraocular pressure (IOP), but there is 
considerable variation in rate of occurrence and side effect 
severity among individuals with GC sensitivity.
GC responsiveness occurs in 10-40% of the normal popu-
lation, and steroid responders are reported to be at increased 
risk of developing primary open angle glaucoma as compared 
with nonresponders [6]. In other clinical studies, occurrence 
of ocular hypertension in healthy individuals was about 7% 
in case of four-week long administration of ﬂuorometholone 
and 35-40% in case of four-week long administration of dexa-
methasone or betamethasone [2,7]. Similar to dexamethasone, 
prednisolone acetate has a high propensity to cause ocular 
hypertension in humans [8].
There is a considerable body of evidence to suggest a role 
for GCs in the pathogenesis of IOP elevation. GC-induced cel-
lular and morphologic changes in trabecular meshwork may 
affect resistance to aqueous humor outﬂow and lead to ocular 
hypertension [9].
In human eyes, GC and mineralocorticoid receptors were 
identiﬁed in multiple types of tissues. Expression of mRNA 
of GC receptor was high in the trabecular meshwork and lens 
epithelium given the effects of GCs in elevated IOP and their 
ability to induce cataract. Expression of mRNAs encoding 
mineralocorticoid receptor was high in nonpigmented ciliary 
epithelium, corneal epithelium, and endothelium [9,10]. Each 
of the major cell types of the cornea produces glucocorticoid 
receptor (GR) [5].
It is presumed that the means by which GCs may lead 
to elevated intraocular pressure is by induction of molecular 
changes in the trabecular meshwork, resulting in morphologic 
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changes and a reduction in aqueous outﬂow. These changes 
include alterations in extracellular matrix production, cell 
size, nuclear size, DNA content, cytoskeletal organization, 
phagocytic activity, and protease activity [6,8,11,12].
GC hormones regulate signal transduction in immune and 
inﬂammatory systems as well as in growth and development. 
GCs exert their effects by binding to and activating GC and 
mineralocorticoid receptors (GR encoded by nuclear subfam-
ily 3, group C, number 1, NR3C1, GeneID; 2908), which are 
present also in ocular tissues.
GR has a series of discrete domains that mediate the 
receptor functions of hormone-binding, DNA-binding, and 
transcriptional modulation [13]. The ligand-receptor com-
plex migrates into the nucleus and binds to the speciﬁc DNA 
sequences called GC response elements (GRE) as a dimer, 
altering the transcription of target genes, which leads to 
altered synthesis of proteins. The N363S polymorphism of 
exon 2 (rs6195) resulting in an asparagine-to-serine change 
at codon 363 was associated with an increased sensitivity to 
glucocorticoids. The molecular mechanism of the effect of 
N363S polymorphism is unknown. However, some authors 
hypothesized that a putative new phosphorylation site may 
alter the protein interactions with transcription cofactors [14-
17]. The Bcl I restriction site polymorphism was identiﬁed as a 
C/G substitution in intron 2 (IVS2+647), and the G allele was 
associated with hypersensitivity to GCs [16-20]. The exonic 
ER22/23EK polymorphism (rs6189, rs6190) consists of a 
synonymous and a nonsynonymous polymorphism. In codon 
22 the nucleotide sequence GAG changes to GAA, both cod-
ing for glutamic acid (E). In codon 23 the nucleotide triplet 
AGG changes to AAG resulting in an amino acid change from 
arginine (R) to lysine (K) [14]. Previous studies demonstrated 
ER22/23EK had an association with a hyposensitivity or a 
relative resistance to GCs [17,21-25]. The allele frequencies 
in the Caucasian race of the examined polymorphisms were 
retrieved from the SNPView Database of Ensembl Genome 
Browser and from recent articles [16,20], and are summerized 
in Table 1.
Heterogeneity in responsiveness to GCs may have thera-
peutic consequences. It may help the choice of the optimal type 
and dosage of steroids: steroid of low or high efﬁcacy, or ste-
roid administration in combination with antiglaucoma drops.
In our study, we examined a group of patients who under-
went treatment with excimer laser PRK and received topical 
steroids as normal postoperative therapy. The decision to ad-
minister either ﬂuorometholone 0.1% or prednisolone acetate 
0.5%, or both, was made based on wound healing response and 
regression of refraction. We investigated whether two exonic 
polymorphisms (N363S and ER22/23EK) and one intronic 
variant (Bcl I) of the GR gene were associated with ocular 
hypertension after topical administration of exogenous GCs.
 
METHODS
Patient selection:  Caucasian patients (n=102) were recruited 
from the excimer laser outpatient clinic at the Department of 
Ophthalmology, Semmelweis University Budapest, Hungary. 
Each patient was asked to ﬁll out a detailed questionnaire about 
medical history and current medications. Individuals with en-
docrine diseases, including diabetes mellitus, were excluded 
from the study. Participating in the study were 45 women and 
57 men. The average age was 35 years (range 21-60 years). The 
mean preoperative IOP was 16.3 mmHg (range 10-21 mmHg). 
All patients underwent PRK and received postoperative topical 
steroids, and gave written consent to participate in the study.
The following selection criteria were used: (1) preopera-
tive IOP less than or equal to 21 mmHg measured by Goldmann 
applanation tonometry; (2) no personal or family history of 
glaucoma; (3) at least two follow-up measurements of IOP, the 
ﬁrst measurement later than the 21st day, the last one between 
5±1 months after the onset of steroid therapy; and (4) continu-
ous steroid administration until the last studied IOP measure-
ment. The same criteria were applied for all analyses.
The study was approved by the ethical committee of 
Ministry of Welfare and met the requirements of the Declara-
tion of Helsinki.
Clinical data analysis:  All participants underwent pre-
operative assessment, which included uncorrected and best 
corrected visual acuity, corneal topography (TMS-1; Tomey, 
Cambridge, MA), slitlamp biomicroscopy, IOP measurement 
with Goldmann applanation tonometry, ultrasound pachymetry 
(Humphrey Model 855; Carl Zeiss, Oberkochen, Germany), 
retinoscopy following cycloplegia, and fundus examination. 
The goal of the operation was to gain emmetropy. Prior to 
PRK refractive surgery, patients were informed of anticipated 
refractive changes and possible consequences. Informed con-
sent was obtained from each patient before the procedure. 
PRK was performed with an Aesculap Meditec Mel 70 and 
80, 193 nm argon-ﬂuorid excimer laser (Carl Zeiss, Jena, 
Germany). Each patient was followed up one and ﬁve days 
postoperatively. Reepithelization of the cornea was normal 
in every case. Patients received topical tobramycin 0.3% ﬁve 
times a day for the ﬁrst seven days; thereafter, topical ﬂuo-
rometholone 0.1% was started ﬁve times daily and continued 
for six to eight months, in a gradually tapered dose. Patients 
came every four to six weeks for follow-up visits depending 
on their status and compliance. In some cases, postoperative 
therapy was changed to prednisolone acetate 0.5% based on 
wound-healing response, subepithelial haze, and regression 
of refraction. Topical prednisolone acetate administration was 
started if haze graded 1.5 or higher according to Hannaʼs scale 
[26] and refractive regression was more than -1.25 D.
To determine whether ﬂuorometholone 0.1% and pred-
nisolone acetate 0.5% raised IOP during postoperative treat-
ment, we divided our study population into three groups: (1) 
patients treated with ﬂuorometholone only (analysis A1, 132 
eyes of 73 patients); (2) patients initially treated with ﬂuoro-
metholone but later switched to prednisolone acetate (analysis 
A2, 42 eyes of 26 patients); and (3) patients treated with pred-
nisolone acetate only (analysis B, 76 eyes of 38 patients). In 
analysis A1 and A2, follow-up of the patients started with the 
date of the initial steroid administration, while in analysis B 
the follow-up started with the date of switch to prednisolone 
acetate administration. After IOP elevation was observed, a 
pressure-lowering therapy was started usually with administra-
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tion of timolol maleate 0.5%. The parts of the measurement 
time series after initiation of IOP-lowering therapies were not 
included in the statistical analysis.
DNA isolation:  Peripheral blood was collected in EDTA-
K3 tubes and DNA was isolated from leukocytes using the 
Wizard DNA Isolation Kit (Promega, Madison, WI).
Allele-speciﬁc PCR for N363S polymorphism:  Allele-
speciﬁc PCR ampliﬁcation was performed with the method de-
signed by Majnik et al. [27] based on the previously described 
oligonucleotide primers by Koper et al. [14]. Allele-speciﬁc 
PCR reaction yielded a control fragment of 357 bp in each tube 
and a speciﬁc fragment of 306 bp in those tubes where the wild 
type allele (coding asparagine) or the mutant allele (coding ser-
ine) corresponding to the applied speciﬁc primer was present. 
Fragments were separated by agarose gel (3%) electrophoresis, 
and visualized by ethidium bromide staining (Figure 1A). We 
used N363N homozygous and N363S heterozygous control 
DNA samples veriﬁed by direct sequencing.
PCR-based restriction fragment length polymorphism 
for intronic BclI polymorphism: DNA was ampliﬁed using a 
standard PCR technique. The forward primer (5ʼ-GAG AAA 
TTC ACC CCT ACC AAC-3ʼ) and the reverse primer (5ʼ-AGA 
GCC CTA TTC TTC AAA CTG-3ʼ) were used at an annealing 
temperature of 56 °C. The reaction mixture was digested with 
BclI restriction enzyme (New England Biolabs, Beverly, MA) 
at 50 °C for 10 h. The ampliﬁed fragment is 418 bp long from 
which the restriction reaction yielded fragments of 263 and 
151 bp for wild-type homozygous samples, fragments of 418, 
263, and 151 bp for heterozygous samples, and a 418 bp frag-
ment, which was detected in polymorphic homozygotes. The 
fragments were separated by agarose gel (2%) electrophoresis, 
stained with ethidium bromide, and documented using ultra-
violet illumination (Figure 1B). Wild-type heterozygous and 
polymorphic homozygous samples, which had been veriﬁed 
by direct DNA sequencing, were used as internal controls.
PCR-based restriction fragment length polymorphism 
for exonic ER22/23EK polymorphism:  The forward primer 
(5ʼ-TGC ATT CGG AGT TAA CTA AAA G-3ʼ) and reverse 
primer (5ʼ-ATC CCA GGT CAT TTC CCA TC-3ʼ) were used 
with a standard PCR protocol; the annealing temperature was 
56 °C. The ampliﬁed fragment was 448 bp long and was di-
gested with MnlI restriction enzyme (New England Biolabs) 
at 37 °C for 4 h. This yielded fragments of 149 and 163 bp 
(and smaller fragments of 50, 49, and 35 bp) in the presence 
of the wild-type allele and fragments of 163 and 184 bp (and 
smaller fragments of 50 and 49 bp) in the presence of the 
polymorphic allele. The fragments were separated by agarose 
gel (3%) electrophoresis, stained with ethidium bromide, and 
documented using ultraviolet illumination (Figure 1C). Wild-
type homozygous and heterozygous samples were sequenced 
and used as internal controls.
Statistical analyses:  Analysis of covariance was used with 
forward stepwise variable selection model biulding. Analysis 
was carried out with the STATISTICA 5.0 software package. 
Maximal IOP during follow-up was studied as the endpoint of 
the analysis; N363S, Bcl I and ER22/23EK were the predictors 
studied; to adjust for possible confounders ablation depth and 
pre-treatment IOP were included into the model. Analysis B 
accounted for a possible further confounder, i.e. duration of 
ﬂuorometholone therapy. As the left eye:right eye correlation 
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TABLE 1. ALLELE FREQUENCIES FOUND IN OUR STUDY POPULATION AND ALLELE FREQUENCIES FOUND IN THE CAUCASIAN POPULATION.
                                                                   Allele
                                                                 frequencies
                           Number                                    in
                             of                                  Caucasian
Polymorphism   Genotype   patients   Allele   Allele frequency   population
------------   --------   --------   ------   ----------------   -----------
N363S           WT:AA        94        A      96.1% (196/204)    91,7-97,9%*
                P:AG          8        G       3.9% (8/204)       2,1%-8,3%*
                P:GG          0
Bcl I           WT:GG        49        G      71.1% (145/204)    71,1-73%**
                P:GC         47        C      28.9% (59/204)     27-28,9%**
                P:CC          6
ER22/23EK       WT:GG        99        G      98.5%(201/204)     97-98,7%*
                P:GC          3        C       1.5% (3/204)       1,3-3%*
                P:CC          0
The genotypic distributions in our study and in literature are shown. Allele frequencies found in our study population are in line with allele 
frequencies found previously in Caucasian population. Homozygotes carrying the polymorphic alleles were not found in our study population 
either in the case of N363S polymorphism nor in the case of ER22/23EK polymorphisms. The asterisk indicates the data was taken from the 
Ensembl Genome Browser SNPView Database. The double asterisk indicates the data were taken from references [16] and [20].
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of the maximal IOP values in patients with both eyes treated 
was higher than 0.9, both eyes of these patients were included 
in the analysis with weights of 0.5. Patients with only one eye 
treated were included with a weight of 1.0.
Photoablation inﬂuencing Goldmann applanation tonom-
etry:  Some authors have expressed concern about the accuracy 
of Goldmann applanation tonometry after refractive surgery, as 
inconsistent results and different proposed correction factors 
were also published. Excimer laser photoablation alters corneal 
thickness and rigidity, which thus inﬂuences Goldman IOP 
measurements. Although photoablation depth did not appear 
as a signiﬁcant covariant in the regression model, we decided 
to exclude the role of this possible confounder by comparing 
the ablation depths of the N363S wild type and heterozygous 
groups. The photoablation depths of the two groups were 
almost identical (wild-type group, mean=84.3, SD=23.5; 
heterozygous group, mean=85.2, SD=27.1).
Choice of boundaries of follow-up period:  In the pilot 
study we did prior to the present study, we found no elevated 
IOPs during the ﬁrst three weeks of follow-up. As a result, 
we chose to ignore IOP measurements before the 21st day 
in this study. We chose 5±1 months as the last measurement 
of the follow-up because we found elevated IOPs were most 
often observed later than three months, but a large number of 
patients did not receive steroid treatment for a period longer 
than six months.
Normal/elevated intraocular pressure versus intraocular 
pressure alteration:  In clinical practice the diagnosis of el-
evated IOP is established by comparison to a threshold value 
(upper boundary of the normal range). In our analyses we did 
not use thresholds; the IOP measured in mmHg was directly 
compared to genetic and other factors. This allowed for detec-
tion of ﬁner correlations.
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Figure 1. Electrophoresis of products of allele-speciﬁc PCR for N363S and PCR-RFLP of Bcl I and ER22/23EK polymorphisms.  A: Allele-
speciﬁc PCR reaction yielded a control fragment of 357 bp in each tube and a speciﬁc fragment of 306 bp in those tubes where the mutant 
allele (coding serine) was present. C1 indicates a wild-type homozygous control. C2 indicates a heterozygous control sample. P1 and P8 are 
patients carrying the polymorphism N363S. P2-P7 and P9 are samples of wild-type patients. A band of 357 bp served as internal control in 
each reaction. B: RFLP analysis using BclI restriction enzyme resulted in fragments of 263, 151 bp for wild-type homozygous samples (C1, 
P2-P5, P8), fragments of 418, 263 and 151 bp for heterozygous samples (C2, P1, P6-P7), and a 418-bp-long fragment for polymorphic homo-
zygotes (C3). C: Analysis of ER22/23EK using MnlI restriction enzyme resulted in fragments of 149 and 163 bp for wild-type homozygous 
samples (C1, P1-P9), and fragments of 163 and 184 bp for heterozygous samples (C2). Abbreviations: M=molecular weight marker, bp=base 
pair, C1-3=control, P1-P9=patients.  
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RESULTS
 Median duration of steroid administration after PRK was 
7.3 months (range: 2.8-30.0 months; 1st quartile/3rd quartile: 
5.8/9.2 months). A switch from ﬂuorometholone 0.1% to pred-
nisolone acetate 0.5% therapy was necessary in 37% of the 
patients after a median ﬂuorometholone 0.1% treatment period 
of three months (1st quartile/3rd quartile: 1.3/6.0 months). 
Median photoablation depth was 84 μm (range 13-118 μm; 
1st quartile/3rd quartile: 60 μm/99 μm).
The results of the genotyping are summarized in Table 
1. Homozygotes carrying the polymorphic alleles were found 
neither in the case of the N363S polymorphism nor in the case 
of the ER22/23EK polymorphism.
Results of analyses A1 and A2:  The mean highest IOP 
during the steroid administration was in analysis A1 and A2 
18.0 mmHg (range: 11-36 mmHg; 1st quartile/median/3rd 
quartile: 16 mmHg/17 mmHg/19 mmHg), 24.8 mmHg (range: 
14-44 mmHg; 1st quartile/median/3rd quartile: 19 mmHg/23 
mmHg/30 mmHg), respectively. The following variables were 
included in the model in the forward stepwise selection pro-
cedure: N363S, Bcl I, ER22/23EK, photoablation depth, and 
initial IOP before steroid treatment. No signiﬁcant predictors of 
the maximal IOP during follow-up were identiﬁed. The forward 
stepwise selection procedure led to the null model. Thus we 
could not prove the effect of any genetic or clinical factors on 
the maximal IOP in the A1 and A2 analyses (Table 2).
Results of analysis B:  Follow-up started at the ﬁrst usage 
of prednisolone acetate 0.5%. Most of the patients were pre-
treated with ﬂuorometholone 0.1% for various durations. The 
mean highest IOP during the prednisolone acetate 0.5% therapy 
was 26.6 mmHg (range: 14-44 mmHg; 1st quartile/median/3rd 
quartile: 22 mmHg/24 mmHg/34 mmHg). The following vari-
ables were included in the forward stepwise variable selection: 
N363S, Bcl I, ER22/23EK, duration of ﬂuorometholone 0.1% 
therapy before prednisolone acetate 0.5% administration, pho-
toablation depth, initial IOP before steroid treatment. After the 
variable selection, only N363S remained in the model, with 
the coefﬁcient of 9.1 mmHg (SE=4.1 mmHg, p=0.03), which 
corresponds to a conﬁdence interval of +1.0 to +17.3 mmHg. 
The other variables did not have a signiﬁcant effect. Thus we 
found signiﬁcant relationship between the N363S heterozygous 
genotype and higher IOP during prednisolone acetate treatment 
(Table 2). Residual analysis showed only minor deviation from 
the normal distribution. This can not substantially deteriorate 
the accuracy of the results of the model because ANOVA is 
known to be robust against deviations from normality.
 
DISCUSSION
Genetic background of glucocorticoid-induced ocular hy-
pertension:  GCs are widely used in clinical practice. It is 
well known that some patients develop side effects, even on 
low dose of GCs, whereas others need a high dose to achieve 
desired results and do not experience any side effects. In oph-
thalmology, steroid responsiveness was ﬁrst described in the 
early 1960s. GC-induced ocular hypertension was observed by 
Armaly [7] after topical treatment of the eye both in healthy 
persons with normal IOP and in patients with glaucoma. Dif-
ferences in ocular response to steroids in humans was believed 
to be genetically linked [7,28,29].
Intraocular pressure response to steroid drugs of differ-
ent efﬁcacy:  GCs, such as ﬂuorometholone and prednisolone 
acetate, normally inhibit wound healing and are capable of 
decreasing corneal edema. Therefore, these drugs are admin-
istered during the postoperative period after excimer laser 
surgery. Fluorometholone and prednisolone acetate are steroid 
drugs of different efﬁcacy. Fluorometholone did not raise IOP 
as much as dexamethasone and prednisolone acetate, which 
have a higher propensity to cause ocular hypertension. Accord-
ing to clinical observations, ﬂuorometholone 0.1% caused a 
6.1±1.4 mmHg (mean±SD) rise, whereas prednisolone acetate 
1.0% caused a 10.0±1.7 mmHg (mean±SD) IOP rise [30,31]. 
In other clinical study on steroid-responders, a six-week-long 
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TABLE 2. MAXIMAL IOP VALUES IN PATIENTS CARRYING VARIOUS ALLELES OF N363S, BCL I, AND ER22/23EK POLYMORPHISMS.
                        Maximal IOP during steroid therapy (mmHg, mean±SD)
                       -----------------------------------------------------
   SNP      Genotype     Analysis A1        Analysis A2        Analysis B
---------   --------   ----------------   ---------------   ----------------
N363S       WT:AA      18.2±4.3 (n=124)   24.4±8.1 (n=37)   23.4±7.9 (n=70)*
            P:AG       16.0±1.2 (n=8)     27.7±6.2 (n=5)    31.0±7.8 (n=6)*
Bcl I       WT:GG      18.4±4.3 (n=64)    26.7±8.4 (n=23)   25.0±8.9 (n=26)
            P:GC,CC    17.7±4.1 (n=68)    22.5±6.8 (n=19)   23.4±7.3 (n=40)
ER22/23EK   WT:GG      18.0±4.3 (n=131)   24.5±8.0 (n=39)   24.0±8.2 (n=72)
            P:GC,CC    19.0 (n=1)         27.8±6.0 (n=3)    26.3±4.9 (n=4)
Patients carrying the G allele of the N363S polymorphism had signiﬁcantly higher maximal IOP during the prednisolone acetate treatment 
(marked with asterisks, p=0.03). Other factors, like frequency of Bcl I and ER22/23EK polymorphisms, photoablation depth, and initial IOP, 
were statistically signiﬁcant neither in analysis groups A1 and A2 nor in analysis group B. Abbreviations: SNP: Single nucleotide polymor-
phism, WT: wild type, P: polymorphic genotype, n: number of eyes studied.
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treatment with ﬂuorometholone 0.5% produced smaller in-
creases in IOP than did dexamethasone 0.1% [32]. In the study 
of Leibowitz et al., in the prednisolone-treated group, mean 
IOP increased signiﬁcantly from 18.1 to 27.1 mmHg [33].
Therefore, we used three groups to examine occurrence 
of steroid-induced ocular hypertension after ﬂuorometholone 
and prednisolone acetate treatment. When we analyzed the 
association of genotypes and steroid-induced ocular hyperten-
sion, we found patients who carryied the N363S polymorphism 
showed signiﬁcantly higher IOP during prednisolone acetate 
treatment. IOP is inﬂuenced by multiple factors, presumably 
the interaction of haplotype and environmental effects. Ac-
cordingly, in our study clinically signiﬁcant IOP elevations 
requiring topical treatment occurred in patients of the wild-
type group as well.
Functional consequences of glucocorticoid receptor 
polymorphisms:  Previous studies on polymorphisms of the 
GR gene examined how changes in nucleotide sequence could 
result in changes in receptor function and in diverse clinical 
manifestations. Most of the mutations were found to be as-
sociated with GC resistance syndromes. However the N363S 
variant and BclI restriction site polymorphism resulted in GC 
hypersensitivity; the ER22/23EK polymorphism was associ-
ated with relative resistance to GCs.
There are at least 16 GR isoforms in a cell, combined 
with several phosphorylation sites, therefore GR presents an 
enormous potential for signaling diversity [34,35]. Various 
parameters determine GC responsiveness, and several proteins 
interact with the GR. The mechanism of GC sensitivity may be 
elucidated by studies on GR-interacting proteins. Transcrip-
tional activation by GR of target genes is subsequent to ligand 
binding, conformational changes, contact with chaperones, 
transcription factors, and other proteins [36]. Polymorphisms 
in GR may change the function of GR-interacting proteins, 
which may inﬂuence sensitivity to GCs. These mechanisms 
may explain variation in responsiveness to GC and GC-induced 
side effects. The ER22/23EK polymorphism resulted in a 
signiﬁcant reduction of transactivating capacity. The N363S 
polymorphism resulted in a signiﬁcantly higher transactivat-
ing capacity. However, neither the ER22/23EK nor the N363S 
polymorphism seemed to inﬂuence the transrepressing capacity 
of the GR [22].
Maximal intraocular pressure versus intraocular pressure 
alteration:  As we evaluated data from this study, we consid-
ered whether to take the maximal IOP during follow-up as the 
dependent variable of the statistical analysis or the individual 
IOP alteration (maximal IOP minus preoperative IOP). Both 
analyses were evaluated, which led to a decisive result. When 
treating IOP alteration as the target of the analysis, the preop-
erative IOP was a signiﬁcant covariate with a coefﬁcient of 
-1.02. As this coefﬁcient was close to -1.0, we concluded it was 
futile to use the preoperative IOP a predictor of maximal IOP 
during steroid treatment. Thus, our analysing method of choice 
targeted the maximal IOP. So the studied factors predict the 
maximal IOP independently of the preoperative IOP. Although 
this ﬁnding enabled us to carry out a simpler analysis, we do not 
recommend this analysis method in general. Certain diseases 
may cause some patients to react in unpredictably.
Effect of previous ﬂuorometholone treatment:  We thought 
about the ﬂuorometholone 0.1% treatment preceding the pred-
nisolone acetate 0.5% treatment to be the better predictor of 
steroid response, so we studied its effect in an additional statis-
tical analysis as well. We forced the duration of previous ﬂuo-
rometholone 0.1% treatment variable into the model, excluding 
it from the stepwise variable selection. The parameter estimate 
corresponding to previous treatment duration was minor and 
nonsigniﬁcant. Thus the effect of the previous ﬂuorometholone 
0.1% treatment seems to be insigniﬁcant compared to the effect 
of prednisolone acetate 0.5% treatment.
In summary, GCs are drugs commonly used to treat 
systemic diseases, such as immune diseases, chronic inﬂam-
mation, or to prevent of rejection of organ grafts. High-dose 
oral GCs may cause side effects, affecting various organs to 
different extents. Each subject, when treated with GCs, needs 
an individually optimized dose to maintain a balance between 
beneﬁcial and adverse effects. By using genotype to identify 
high-risk steroid responders may allow for individualized 
therapy, enabling the avoidance of GC side effects. In order 
to optimize individual GC treatments, N363S genotyping may 
become everyday practice.
In our study of a modest number of cases, we showed 
that the N363S polymorphism of the GC receptor gene was 
signiﬁcantly associated with increased IOP as response to 
prednisolone acetate 0.5% therapy after PRK. In the future, 
N363S genotyping before steroid treatment may have a role 
in preventing steroid-induced high IOP.
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